Evolution in the diagnosis and treatment of breast cancer: a PRISMA 2020 systematic review
DOI:
https://doi.org/10.56294/dm2024.334Keywords:
prevalence, breast cancer, systematic review, epidemiology, public healthAbstract
Breast cancer is the most common neoplasm and one of the leading causes of cancer-related mortality in women worldwide, presenting significant challenges in diagnosis, treatment, and prevention. The objective of the study was to systematically and critically review the scientific literature published between 2020 and 2024 on breast cancer, with an emphasis on advances in diagnostics, therapeutics, and the understanding of its risk factors and biomarkers, to identify trends and gaps in current knowledge. A systematic review was conducted following PRISMA 2020 guidelines, analyzing 19,038 articles identified in PubMed, from which 10 key studies were selected based on their relevance, methodological quality, and significant contributions. The results show that the integration of genomic, immunohistochemical, and immunological biomarkers has improved diagnosis and treatment personalization, especially in aggressive subtypes such as triple-negative breast cancer. Prevention is progressing with models integrating factors like mammographic density and polygenic risk, although barriers to implementation persist. Moreover, global disparities in diagnosis and treatment reflect structural inequities, particularly in low- and middle-income countries. Innovations in targeted therapies are expanding options for advanced and metastatic cases. In conclusion, diagnostic and therapeutic strategies for breast cancer have evolved significantly during the studied period, contributing to a more personalized and effective approach, yet challenges related to equity, accessibility, and the global implementation of advancements remain
References
1. Katsura C, Ogunmwonyi I, Kankam HK, Saha S. Breast cancer: presentation, investigation and management. Br J Hosp Med (Lond). 2022 Feb 2;83(2):1-7. doi: 10.12968/hmed.2021.0459
2. Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E, Farahmand L. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020 Jul;84:106535. doi: 10.1016/j.intimp.2020.106535.
3. Donahue PMC, MacKenzie A, Filipovic A, Koelmeyer L. Advances in the prevention and treatment of breast cancer-related lymphedema. Breast Cancer Res Treat. 2023 Jul;200(1):1-14. doi: 10.1007/s10549-023-06947-7. Epub 2023 Apr 27.
4. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021 May 8;397(10286):1750-1769. doi: 10.1016/S0140-6736(20)32381-3. Epub 2021 Apr 1. Erratum in: Lancet. 2021 May 8;397(10286):1710. doi: 10.1016/S0140-6736(21)00838-2.
5. Bodewes FTH, van Asselt AA, Dorrius MD, Greuter MJW, de Bock GH. Mammographic breast density and the risk of breast cancer: A systematic review and meta-analysis. Breast. 2022 Dec;66:62-68. doi: 10.1016/j.breast.2022.09.007
6. Boere I, Lok C, Poortmans P, Koppert L, Painter R, Vd Heuvel-Eibrink MM, Amant F. Breast cancer during pregnancy: epidemiology, phenotypes, presentation during pregnancy and therapeutic modalities. Best Pract Res Clin Obstet Gynaecol. 2022 Jun;82:46-59. doi: 10.1016/j.bpobgyn.2022.05.001.
7. Britt KL, Cuzick J, Phillips KA. Key steps for effective breast cancer prevention. Nat Rev Cancer. 2020 Aug;20(8):417-436. doi: 10.1038/s41568-020-0266-x.
8. Benitez Fuentes JD, Morgan E, de Luna Aguilar A, Mafra A, Shah R, Giusti F, Vignat J, Znaor A, Musetti C, Yip CH, Van Eycken L, Jedy-Agba E, Piñeros M, Soerjomataram I. Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024 Jan 1;10(1):71-78. doi: 10.1001/jamaoncol.2023.4837.
9. Scudeler MM, Manóchio C, Braga Pinto AJ, Santos Cirino HD, da Silva CS, Rodrigues-Soares F. Breast cancer pharmacogenetics: a systematic review. Pharmacogenomics. 2023 Jan;24(2):107-122. doi: 10.2217/pgs-2022-0144.
10. Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther. 2021 Feb;21(2):135-148. doi: 10.1080/14737140.2021.1840984.
11. Grabinski VF, Brawley OW. Disparities in Breast Cancer. Obstet Gynecol Clin North Am. 2022 Mar;49(1):149-165. doi: 10.1016/j.ogc.2021.11.010
12. Trapani D, Ginsburg O, Fadelu T, Lin NU, Hassett M, Ilbawi AM, Anderson BO, Curigliano G. Global challenges and policy solutions in breast cancer control. Cancer Treat Rev. 2022 Mar;104:102339. doi: 10.1016/j.ctrv.2022.102339.
13. Arafat HM, Omar J, Shafii N, Naser IA, Al Laham NA, Muhamad R, Al-Astani TAD, Shaqaliah AJ, Shamallakh OM, Shamallakh KM, Abusalah MAH. The association between breast cancer and consumption of dairy products: a systematic review. Ann Med. 2023 Dec;55(1):2198256. doi: 10.1080/07853890.2023.2198256.
14. Alvarado-Pico E, Llerena-Gómez C, Sotalin-Nivela E. Evaluación de concordancia inter-observador entre radiólogo y estudiantes en detección de lesiones mamarias en mamografías. Revista Cubana de Investigaciones Biomédicas [Internet]. 2024 [citado 10 Abr 2024]; 43 Disponible en: https://revibiomedica.sld.cu/index.php/ibi/article/view/3259.
Published
Issue
Section
License
Copyright (c) 2024 Julio Rodrigo Morillo Cano , Mely Anahí Castro Galárraga, Fátima Fernanda Orbe Cerón (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
